In samples of two nilotinib-pretreated CML patients with diabetes mellitus using gliptins for diabetic control, BCR-ABL1 transcripts were near undetectable or undetectable [16]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.